Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synriam versus Coartem for uncomplicated falciparum malaria in adolescents and adults in Nigeria
PACTR202305878745601Phase 4Completed
- Sponsor
- Ranbaxy Nigeria
- Start
- Jun 2023
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Malaria comparing Synriam arm with Coartem arm (2 arms). Primary endpoint: Day 28 PCR-corrected adequate clinical and parasitological response. Started Jun 2023; status: completed.
02
Drugs
Arterolanelumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202305878745601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202305878745601.